Agios Pharmaceuticals AGIO Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's other income, net (note 6)?
- Agios Pharmaceuticals (AGIO) reported other income, net (note 6) of $119K in Q1 2026.
- How has Agios Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Agios Pharmaceuticals's other income, net (note 6) decreased by 90.5% year-over-year, from $1.25M to $119K.
- What is the long-term trend for Agios Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's other income, net (note 6) has grown at a -39.3% compound annual growth rate (CAGR), from $14.43M to $1.96M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.